XML 88 R77.htm IDEA: XBRL DOCUMENT

Net Income (Loss) Per Share Attributable to Common Shareholders (Details) - Schedule of securities excluded from computation of diluted net income (loss) per share - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Schedule of securities excluded from computation of diluted net income (loss) per share [Abstract]
Series D redeemable convertible preferred stock		9,394,057		9,394,057
Series C redeemable convertible preferred stock		7,264,519		7,264,519
Series B redeemable convertible preferred stock		4,168,815		4,168,815
Series A redeemable convertible preferred stock		16,066,503		16,066,503
Series D redeemable convertible preferred stock warrants		320,441		320,441
Series A redeemable convertible preferred stock warrants		1,608,670		1,608,670
Convertible notes payable (see Note 11)			482,703
Common stock warrants (see Note 10)	2,523,351		4,569,962
Options to purchase common stock	2,685,575	7,509,810	9,063,423	7,509,810
Restricted stock awards	1,100,050		1,245,489
Chardan Unit Purchase Option Warrants (see Notes 3 and 10)	24,583		24,583
Clene Nanomedicine contingent earn-out shares (see Note 3 and 12)	8,346,185		8,346,185
Initial Shareholders contingent earn-out shares (see Note 3 and 12)	750,000		750,000
Total	15,429,744	46,332,815	24,482,345	46,332,815